RT Journal Article
SR Electronic
T1 Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.24.21253992
DO 10.1101/2021.03.24.21253992
A1 Jonathan Klein
A1 Anderson F. Brito
A1 Paul Trubin
A1 Peiwen Lu
A1 Patrick Wong
A1 Tara Alpert
A1 Mario A. Peña-Hernández
A1 Winston Haynes
A1 Kathy Kamath
A1 Feimei Liu
A1 Chantal B. F. Vogels
A1 Joseph R. Fauver
A1 Carolina Lucas
A1 Jieun Oh
A1 Tianyang Mao
A1 Julio Silva
A1 Anne L. Wyllie
A1 M. Catherine Muenker
A1 Arnau Casanovas-Massana
A1 Adam J. Moore
A1 Mary E. Petrone
A1 Chaney C. Kalinich
A1 Yale IMPACT Research Team
A1 Charles Dela Cruz
A1 Shelli Farhadian
A1 Aaron Ring
A1 John Shon
A1 Albert I. Ko
A1 Nathan D. Grubaugh
A1 Benjamin Israelow
A1 Akiko Iwasaki
A1 Marwan M. Azar
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.24.21253992.abstract
AB Prior to the emergence of antigenically distinct SARS-CoV-2 variants, reinfections were reported infrequently - presumably due to the generation of durable and protective immune responses. However, case reports also suggested that rare, repeated infections may occur as soon as 48 days following initial disease onset. The underlying immunologic deficiencies enabling SARS-CoV-2 reinfections are currently unknown. Here we describe a renal transplant recipient who developed recurrent, symptomatic SARS-CoV-2 infection - confirmed by whole virus genome sequencing - 7 months after primary infection. To elucidate the immunological mechanisms responsible for SARS-CoV-2 reinfection, we performed longitudinal profiling of cellular and humoral responses during both primary and recurrent SARS-CoV-2 infection. We found that the patient responded to the primary infection with transient, poor-quality adaptive immune responses. The patient’s immune system was further compromised by intervening treatment for acute rejection of the renal allograft prior to reinfection. Importantly, we also identified the development of neutralizing antibodies and the formation of humoral memory responses prior to SARS-CoV-2 reinfection. However, these neutralizing antibodies failed to confer protection against reinfection, suggesting that additional factors are required for efficient prevention of SARS-CoV-2 reinfection. Further, we found no evidence supporting viral evasion of primary adaptive immune responses, suggesting that susceptibility to reinfection may be determined by host factors rather than pathogen adaptation in this patient. In summary, our study suggests that a low neutralizing antibody presence alone is not sufficient to confer resistance against reinfection. Thus, patients with solid organ transplantation, or patients who are otherwise immunosuppressed, who recover from infection with SARS-CoV-2 may not develop sufficient protective immunity and are at risk of reinfection.Competing Interest StatementAI served as a consultant for Spring Discovery, Boehringer Ingelheim, and Adaptive Biotechnologies.Funding StatementThis work was supported by the Womens Health Research at Yale Pilot Project Program (A.I.), Fast Grant from Emergent Ventures at the Mercatus Center (A.I. and N.D.G), Mathers Foundation, the Ludwig Family Foundation, the Department of Internal Medicine at the Yale School of Medicine, Yale School of Public Health, the Beatrice Kleinberg Neuwirth Fund, and CDC Contract # 75D30120C09570 (N.D.G.). IMPACT received support from the Yale COVID-19 Research Resource Fund. A.I. is an Investigator of the Howard Hughes Medical Institute. J.K. received support from NIH T32 MSTP training grant. B.I received support from NIAID 2T32AI007517-16. T.A. and M.E.P were supported by CTSA Grant Number TL1 TR001864.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, protocol ID 2000027690). Informed consent was obtained from all enrolled patients and healthcare workers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCorrespondence and requests regarding clinical features of this manuscript should be addressed to M.A. Other correspondence and requests should be addressed to A.I. and B.I.